Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zosano Pharma Corporation (NASDAQ: ZSAN).

Full DD Report for ZSAN

You must become a subscriber to view this report.


Recent News from (NASDAQ: ZSAN)

Zosano Pharma to Present Phase 3 Safety Study Update for ADAM(TM) Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
FREMONT, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leverag...
Source: GlobeNewswire
Date: September, 06 2018 08:30
Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine Trust International Symposium (MTIS)
FREMONT, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its propr...
Source: GlobeNewswire
Date: September, 05 2018 08:30
Zosano Pharma Corporation (ZSAN) CEO John Walker on Q2 2018 Results - Earnings Call Transcript
Zosano Pharma Corporation (ZSAN) Q2 2018 Earnings Conference Call August 09, 2018 4:30 PM ET Executives Carol Lizak - Senior Director and Corporate Controller John Walker - Chief Executive Officer Donald Kellerman - Vice President of Clinical Development & Medical Affairs P...
Source: SeekingAlpha
Date: August, 09 2018 21:53
Zosano Pharma reports Q2 results
Zosano Pharma (NASDAQ: ZSAN ): Q2 EPS of -$0.75 More news on: Zosano Pharma, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:13
Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update
Completed enrollment for our M207-ADAM study with 344 subjects Presented additional analyses from the ZOTRIP pivotal study on pain relief and recurrence at the 2018 American Headache Society (AHS) meeting Published M207 nonclinical data in multiple leading scientific journals ...
Source: GlobeNewswire
Date: August, 09 2018 16:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-133.65013.633.773.6359,551
2018-12-123.603.673.773.5961,417
2018-12-113.633.603.703.5563,752
2018-12-103.75783.663.773.55147,570
2018-12-073.753.77013.8483.7511,363

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1312,42929,77841.7389Short
2018-12-121,35912,88910.5439Cover
2018-12-112,15918,64311.5808Cover
2018-12-109,17749,88618.3959Cover
2018-12-071,2004,92524.3655Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZSAN.


About Zosano Pharma Corporation (NASDAQ: ZSAN)

Logo for Zosano Pharma Corporation (NASDAQ: ZSAN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $8,503,798 - 05/18/2018
  • Issue and Outstanding: 1,973,039 - 03/01/2018

 


Recent Filings from (NASDAQ: ZSAN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 06 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: July, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 12 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: June, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 05 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018

 

 


Daily Technical Chart for (NASDAQ: ZSAN)

Daily Technical Chart for (NASDAQ: ZSAN)


Stay tuned for daily updates and more on (NASDAQ: ZSAN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ZSAN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZSAN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZSAN and does not buy, sell, or trade any shares of ZSAN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/